Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Increases By 67.2%

Posted by Defense World Staff on Mar 30th, 2025

180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 56,000 shares, a growth of 67.2% from the February 28th total of 33,500 shares. Approximately 4.1% of the company’s stock are short sold. Based on an average daily trading volume, of 392,200 shares, the days-to-cover ratio is presently 0.1 days.

180 Life Sciences Stock Performance

180 Life Sciences stock opened at $1.03 on Friday. The stock’s 50 day moving average is $1.27 and its 200 day moving average is $1.98. 180 Life Sciences has a twelve month low of $0.98 and a twelve month high of $17.75.

Hedge Funds Weigh In On 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Rathbones Group PLC acquired a new stake in shares of 180 Life Sciences Corp. (NASDAQ:ATNF – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned approximately 2.20% of 180 Life Sciences as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 4.07% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 180 Life Sciences in a research report on Saturday, March 22nd.

Read Our Latest Research Report on ATNF

About 180 Life Sciences

(Get Free Report)

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.